Work

Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma

Year: 2024

Type: review

Abstract: The ECHELON-1 trial demonstrated the effectiveness of brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine as a frontline treatment regimen in classical Hodgkin lymphoma. However, peripheral neuropathy (PN) is common with this regimen, occurring in up to two-thirds of patients. While standard prescribing information recommends BV dose modification at the onset of grade 2 PN, management strategies for PN are not well-defined. Most commonly, clinicians dose reduce or discontinue BV, vinblastine, or both. We review evidence-based and practical approaches for managing peripheral neuropathy, emphasizing early detection and dose modification.

Source: Critical Reviews in Oncology/Hematology

DOI: 10.1016/j.critrevonc.2024.104499

Authors: Jeremy S. Abramson, Robert Stuver, Alex Herrera, Emily Patterson, Yi-Ping Wen, Alison Moskowitz

Institutions: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, City of Hope

Language: English

Topic: Cancer Treatment and Pharmacology

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,690